✦ LIBER ✦

A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia

✍ Scribed by Astrid Gruber; Magnus Björkholm; Lorentz Brinch; Stein Evensen; Bengt Gustavsson; Michael Hedenus; Gunnar Juliusson; Eva Löfvenberg; Ingerid Nesthus; Bengt Simonsson; Malvin Sjo; Leif Stenke; Jon Magnus Tangen; Ulf Tidefelt; Ann-Mari Udén; Christer Paul; Jan Liliemark

Book ID: 108403255
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 70 KB
Volume: 27
Category: Article
ISSN: 0145-2126
DOI: 10.1016/s0145-2126(02)00181-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of refractory acute myeloid le

Treatment of refractory acute myeloid leukemia with mAMSA and VP 16-213 in combination: Results of a clinical phase I/II study

✍ Wolfgang Hiddemann; Dieter Urbanitz; Peter Preusser; Wolf Achterrath; Thomas Büc 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 482 KB

Twenty patients with refractory AML were treated with mAMSA and VP 16-2 13 in combination to assess the toxicity and anti-leukemic activity of the two-drug regimen. Refractoriness was defined according to the response to induction therapy consisting of 6-thioguanine, cytosine arabinoside and daunoru

A phase I study of recombinant human sol

A phase I study of recombinant human soluble interleukin-1 receptor (rhu IL-1R) in patients with relapsed and refractory acute myeloid leukemia

✍ Steven H. Bernstein; Joseph Fay; Stanley Frankel; Neal Christiansen; Maria R. Ba 📂 Article 📅 1999 🏛 Springer 🌐 English ⚖ 77 KB

Phase III study of PSC-833 (valspodar) i

Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95) : A trial of the Eastern Cooperative Oncology Group

✍ William R. Friedenberg; Montserrat Rue; Emily A. Blood; William S. Dalton; Chaim 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB 👁 1 views

Results of a phase 2 study of valproic a

Results of a phase 2 study of valproic acid alone or in combination with all-transretinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia

✍ Andrea Kuendgen; Sabine Knipp; Frank Fox; Corinna Strupp; Barbara Hildebrandt; C 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 97 KB

High-dose cytosine arabinoside and dauno

High-dose cytosine arabinoside and daunorubicin as primary therapy in elderly patients with acute myelogenous leukemia. A phase I-II study of the southeastern cancer study group

✍ Hillard M. Lazarus; W. Ralph Vogler; C. Patrick Burns; Elliott F. Winton 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 571 KB

Fractionated doses of gemtuzumab ozogami

Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50–70-year old: A phase 1/2 study of the acute leukemia French association

✍ Hassan Farhat; Oumedaly Reman; Emmanuel Raffoux; Celine Berthon; Cécile Pautas; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB 👁 1 views